Dies ist eine HTML Version eines Anhanges der Informationsfreiheitsanfrage 'Documents regarding endocrine disruptors SG'.

Ref. Ares(2016)1853543 - 19/04/2016
Ref. Ares(2016)1974946 - 26/04/2016
18 September 2015 10:38 


RE: Meeting with ECPA 
Dear Ms 

Thank you for your email. I have been in contact with Mr 
 and Mr 
 who are 
working on these matters in the Secretariat General, and they will be happy to meet with you.  
I have put them in copy to this email and I would advise you to contact them in order to set up a 
Member of Cabinet 
Cabinet of Vice President Jyrki Katainen 
Jobs, Growth, Investment and Competitiveness 
European Commission 
BERL 10/
B-1049 Brussels/Belgium 
Office: +32 2 29 
Mobile: +32 
Sent: Monday, September 14, 2015 5:21 PM 
Subject: Meeting with ECPA 
As mentioned in a meeting with Mr 
 in April, and referred to in the email below, 
ECPA is facing important hurdles preventing our member companies to put new, innovative 
plant protection products on the market in a timely manner. Since these hurdles recently 
increased and call for an urgent solution, we would like to kindly request a meeting in order to 
update you on the new procedural obstacles which our members reported on, especially   

On the setting of Maximum Residue Levels that affect the approval of new active 

On the interim definition of Endocrine Disruption which is not scientifically based and 
may hit safe active substances  
For such a meeting we would like to propose the following times: 
¾  Friday 18th September, between 1500-1700 hours 
¾  Monday 21st September, before 1500 hours 
¾  Tuesday 22nd September, all day 
¾  Wednesday 23rd September, before 1500 hours 
ECPA would be represented by Euros Jones and myself.  
We hope that you will be able to reply positively to this request,  
Best regards,  
ECPA aisbl 
6 Avenue E. Van Nieuwenhuyse 
1160 Brussels, Belgium 
Tel: +32 2 
Fax: +32 2 
EU Transparency Register ID N° 0711626572-26 
Sent: 22 April 2015 17:44 
To: '
Subject: Meeting with ECPA: Follow-up 
Thank you for your time yesterday. I found it useful and I hope that the information on our 
sector was useful. I appreciated your particular focus on innovation as this is a key area for our 
companies; as I mentioned, the R&D budget exceeds €2 billion annually - but with a growing 
percentage being focussed on non-EU markets. If I can provide any additional information, 
please let me know. 
We also briefly discussed the new procedures and the impact on the decision making procedure 
on decision making, with the impact being a delay in the entry onto the market of new 
innovation. We hope that delays will only be short term but as I mentioned, we do plan to write 
to Commissioner Timmermans on this issue and we will of course keep you informed. 

We only had a brief moment to discuss endocrine disruptors and as mentioned, this is very much 
in the assessment phase in DG SANTE at the moment. But I would welcome the opportunity to 
further discuss this issue with you when the assessment nears completion. 
If you require any additional information, please do not hesitate to contact me. 
Thanks again and best regards 
European Crop Protection Association, aisbl 
Tel: +32 2 
 (direct);  +32 2 
Tel: +32 
 (GSM - Mobile) 
EU Transparency Register ID N° 0711626572-26